Purpose: Although dysphonia has been shown to be a common sign of Huntington disease (HD), the extent of phonatory dysfunction in gene positive premanifest HD individuals remains unknown. The aim of the current study was to explore the possible occurrence of phonatory abnormalities in prodromal HD.
Method: Sustained vowel phonations were acquired from 28 premanifest HD individuals and 28 healthy controls of comparable age. Data were analysed acoustically for measures of several phonatory dimensions including airflow insufficiency, aperiodicity, irregular vibration of vocal folds, signal perturbations, increased noise, vocal tremor and articulation deficiency. A predictive model was built to find the best combination of acoustic features and estimate sensitivity/specificity for differentiation between premanifest HD subjects and controls. The extent of voice deficits according to a specific phonatory dimension was determined using statistical decision making theory. The results were correlated to global motor function, cognitive score, disease burden score and estimated years to disease onset.
Results: Measures of aperiodicity and increased noise were able to significantly differentiate between premanifest HD individuals and controls (p<0.01). The combination of these aspects of dysphonia led to a sensitivity of 91.5% and specificity of 79.2% to correctly distinguish speakers with premanifest HD from healthy individuals. Some form of disrupted phonatory function was revealed in 68% of our premanifest HD subjects, where 18% had one affected phonatory dimension and 50% showed impairment of two or more dimensions. A relationship between pitch control and cognitive score was also observed (r = -0.50, p = 0.007).
Conclusions: Phonatory abnormalities are detectable even the in premotor stages of HD. Speech investigation may have the potential to provide functional biomarkers of HD and could be included in future clinical trials and therapeutic interventions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237453 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113412 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Impact of Upper Limb Function on Activities of Daily Living and Quality of Life in Huntington's Disease.
J Clin Med
December 2024
Neurology Department, Burgos University Hospital, 09006 Burgos, Spain.
: Huntington's disease (HD) is a neurodegenerative movement disorder associated with significant disability and impairment of Activities of Daily Living (ADLs). The impact of upper limb disability on quality of life (QoL) and its influence on ADLs is not well known yet. The aim of this study was to describe the manipulative dexterity, strength, and manual eye coordination of patients with manifest and premanifest-HD compared to healthy individuals and to analyze its influence on ADLs and QoL.
View Article and Find Full Text PDFLRRK2 mutation contributes to decreased free water in the nucleus basalis of Meynert in manifest and premanifest Parkinson's disease.
J Neurol
December 2024
Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Background: Free-water imaging can predict and monitor dopamine system degeneration in patients with Parkinson's disease (PD). However, brain cholinergic function has not been investigated to date in LRRK2 mutation carriers with or without PD using free-water imaging.
Objectives: To investigate the effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of PD using free-water imaging.
Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.
J Neurol
December 2024
Department of Neurology, Leiden University Medical Center, PO 9600, 2300RC, Leiden, The Netherlands.
Background: Proper medication reconciliation (= comparing the accuracy of patient-reported medication use with pharmacy records) could prevent potentially dangerous situations such as drug-drug interactions and hospitalization. This is particularly important when patients rely on multiple medications, such as in neurodegenerative disorders like Huntington's Disease (HD). Currently, it is unknown how often medication discrepancies occur in HD patients and which factors contribute to the discrepancies.
View Article and Find Full Text PDFβ-Blocker Use and Delayed Onset and Progression of Huntington Disease.
JAMA Neurol
January 2025
Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City.
Importance: Huntington disease (HD) is characterized by motor, cognitive, and psychiatric decline. β-Blockers may play a therapeutic role by decreasing enhanced sympathetic tone in HD.
Objective: To evaluate the impact of β-blockers on the timing of motor diagnosis onset and progression of HD symptoms.
Shifting focus from ideality to reality: a qualitative study on how quality of life is defined by premanifest and manifest Huntington's disease gene expansion carriers.
Orphanet J Rare Dis
November 2024
Department of Public Health and Primary Care, Leiden University Medical Center, Postzone V0-P, PO Box 9600, 2300 RC, Leiden, The Netherlands.
Article Synopsis
- Understanding quality of life (QoL) is crucial for diseases like Huntington's disease (HD), yet few studies focus on how gene expansion carriers (HDGECs) perceive their own QoL.
- This qualitative study interviewed 12 HDGECs (6 premanifest and 6 manifest) in the Netherlands to explore their definitions of QoL, revealing distinct themes for each group.
- Results showed that premanifest HDGECs focused on meaningful life concerns while manifest HDGECs dealt with adapting to reality, emphasizing the need for personalized care strategies that acknowledge the shifting perspectives of HDGECs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!